Maria João Bugalho

Prof. Maria João Bugalho

Head of Endocrine Department, CHULN-Hospital de Santa Maria, Lisboa
+1
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
FCFrederic Castinetti
Frederic Castinetti
XQXiao-Ping Qi
Xiao-Ping Qi
MWMartin K Walz
Martin K Walz
AMAna Luiza Maia
Ana Luiza Maia
GSGabriela Sansó
Gabriela Sansó
HNHartmut P H Neumann
Hartmut P H Neumann

28 April 2009 in British Journal of Cancer
Verified
Journal Article
Open access
MMM M Moura
M M Moura
BCBranca Maria Cavaco
Branca Maria Cavaco
APA E Pinto
A E Pinto
RDR Domingues
R Domingues
JSJ R Santos
J R Santos
VLValeriano Leite
Valeriano Leite
Screening of REarranged during Transfection (RET) gene mutations has been carried out in different series of sporadic medullary thyroid carcinomas (MTC). RET-positive tumours seem to be associated to a worse clinical outcome. However, the correlation between the type of RET mutation and the patients' clinicopathological data has not been evaluated yet. We analysed RET exons 5, 8, 10–16 in fifty-one sporadic MTC, and found somatic mutations in thirty-three (64.7%) tumours. Among the RET-positive cases, exon 16 was the most frequently affected (60.6%). Two novel somatic mutations (Cys630Gly, c.1881del18) were identified. MTC patients were divided into three groups: group 1, with mutations in RET exons 15 and 16; group 2, with other RET mutations; group 3, having no RET mutations. Group 1 had higher prevalence (P=0.0051) and number of lymph node metastases (P=0.0017), and presented more often multifocal tumours (P=0.037) and persistent disease at last control (P=0.0242) than group 2. Detectable serum calcitonin levels at last screening (P=0.0119) and stage IV disease (P=0.0145) were more frequent in group 1, than in the other groups. Our results suggest that, among the sporadic MTC, cases with RET mutations in exons 15 and 16 are associated with the worst prognosis. Cases with other RET mutations have the most indolent course, and those with no RET mutations have an intermediate risk.

1 March 2019 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
FCFrederic Castinetti
Frederic Castinetti
SWSteven G Waguespack
Steven G Waguespack
AMAndreas Machens
Andreas Machens
SUShinya Uchino
Shinya Uchino
KHKornelia Hasse-Lazar
Kornelia Hasse-Lazar
EBEric Baudin
Eric Baudin

5 July 2005 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Maria João BugalhoMaria João Bugalho
Maria João Bugalho
JSJorge Rosa Santos
Jorge Rosa Santos
LSLuís Sobrinho
Luís Sobrinho

29 October 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
VCVasileios Chortis
Vasileios Chortis
IBIrina Bancos
Irina Bancos
TNThomas Nijman
Thomas Nijman
LGLorna C Gilligan
Lorna C Gilligan
ATAngela E Taylor
Angela E Taylor
WAWiebke Arlt
Wiebke Arlt
Context: Urine steroid metabolomics, combining mass spectrometry-based steroid profiling and machine learning, has been described as a novel diagnostic tool for detection of adrenocortical carcinoma (ACC). Objective, Design, Setting: This proof-of-concept study evaluated the performance of urine steroid metabolomics as a tool for postoperative recurrence detection after microscopically complete (R0) resection of ACC. Patients and Methods: 135 patients from 14 clinical centers provided postoperative urine samples, which were analyzed by gas chromatography–mass spectrometry. We assessed the utility of these urine steroid profiles in detecting ACC recurrence, either when interpreted by expert clinicians or when analyzed by random forest, a machine learning-based classifier. Radiological recurrence detection served as the reference standard. Results: Imaging detected recurrent disease in 42 of 135 patients; 32 had provided pre- and post-recurrence urine samples. 39 patients remained disease-free for ≥3 years. The urine “steroid fingerprint” at recurrence resembled that observed before R0 resection in the majority of cases. Review of longitudinally collected urine steroid profiles by 3 blinded experts detected recurrence by the time of radiological diagnosis in 50% to 72% of cases, improving to 69% to 92%, if a preoperative urine steroid result was available. Recurrence detection by steroid profiling preceded detection by imaging by more than 2 months in 22% to 39% of patients. Specificities varied considerably, ranging from 61% to 97%. The computational classifier detected ACC recurrence with superior accuracy (sensitivity = specificity = 81%). Conclusion: Urine steroid metabolomics is a promising tool for postoperative recurrence detection in ACC; availability of a preoperative urine considerably improves the ability to detect ACC recurrence.

9 November 2014 in Endocrine
Verified
Journal Article
Closed access
PDF file
JPJoana S. Pereira
Joana S. Pereira
JSJoana Gomes da Silva
Joana Gomes da Silva
RTRute Alexandra Tomaz
Rute Alexandra Tomaz
APAntónio Evaristo Pinto
António Evaristo Pinto
Maria João BugalhoMaria João Bugalho
Maria João Bugalho
BCBranca Maria Cavaco
Branca Maria Cavaco